Sign in
Taking peoplePhase 1/2

Minocycline for long-lasting autoimmune uveitis with retinal degeneration

Tests minocycline in adults with chronic autoimmune uveitis and retinal degenerative changes.

Key facts

Who runs it
Sun Yat-sen University
Where
China1 site in 1 countryChoose a country to see its sites
Trial code
Registry title
Minocycline for Chronic Autoimmune Uveitis
Status
Recruiting
Phase
Phase 1/2
People taking part
10 people, planned
Started
1 Dec 2021
Expected to end
31 Dec 2026
Type of study
Interventional
Treatments tested
  • minocycline
Record updated
18 April 2023

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with chronic autoimmune uveitis (long-lasting inflammation inside the eye caused by the immune system) whose vision has been damaged. It tests minocycline.

Age
The criteria say 18-60 years old. The record's age limits say 18 Years to 70 Years.
Sex
All sexes can join.
Disease stage
An autoimmune disease with damage to vision, such as lower best-corrected sight (BCVA) or loss of retinal structure.
Earlier treatment
People currently using glucocorticoids, immunosuppressants or biologics cannot join.

Main reasons for not taking part

  • Allergy to minocycline or tetracyclines
  • Abnormal liver, heart, kidney or thyroid function
  • Currently using glucocorticoids, immunosuppressants or biologics
  • Pregnant, breast-feeding or planning to become pregnant
  • Currently using other medicines for other diseases

The registry criteria, word for word

Show all 9 criteriaShow less

Who can take part

  • Participant diagnosed of autoimmune diseases with visual function damage (decrease of BCVA, loss of retinal structure)
  • Participant aged from 18-60 years old
  • Participant that signed the informed consent document and is able to complete the following visits

Who cannot take part

  • Participant that is currently using other medications for other diseases
  • Participant is allergy to minocycline or tetracyclines
  • Participant has an abnormal function of liver, heart, kidney and thyroid
  • Participant has no contraindications of minocycline or tetracyclines
  • Participant is using glucocorticoids, immunosuppressants or biologics
  • Female that is pregnant, breast-feeding or planning to become pregnant

The main criteria, as questions

These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Are you between 18 and 70 years old?

This trial is currently available in China.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Autoimmune uveitis is one kind of non-infectious, sight-threatening, relapsing and severe ocular disease. Approximately 20%-25% autoimmune uveitis patients suffer from the dilemma of blindness for the chronic and persistent inflammatory state in the eyes, which results in continuous destroy in the structure of the eyes and gradually leads to irreversible damage on visual function. However, it shows limiting efficacy of current treatment including glucocorticoids, immunosuppressant and biologics for chronic autoimmune uveitis. Minocycline has been regarded to have anti-apoptosis and immunemodulatory function for decades and it has been illustrated to be beneficial in several neuro-degenerative and neuro-inflammatory diseases. This trial aims to investigate the efficacy and safety of minocycline for chronic autoimmune uveitis with retinal degenerative changes.

The group in the trial

  • minocyclineTreatment being tested

    minocycline capsule 100mg per day orally

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
The Efficacy and Safety of Minocycline for Chronic Autoimmune Uveitis
Plain-language title
Minocycline for long-lasting autoimmune uveitis with retinal degenerationGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 15 November 2026.
Criteria questions
Built from NCT05474729, who can take part
Record updated
18 April 2023